Equity Research Medical Devices

Should You Buy Abbott Laboratories Stock in 2026?

By CirclFi Research Team · · 13/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Abbott Laboratories (ABT) ranks in the top tier of our coverage universe with a Quality of Company score of 10.0/10. Trading at a market price of $100.67, this high-quality profile requires careful comparison against our 13 intrinsic value models.

The short answer: 2 of 13 CirclFi valuation models project upside for Abbott Laboratories (ABT) at $100.67 — the model consensus leans bearish, with a Quality Score of 10.0/10 and Value-Trap risk of —/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 11 of 13 models suggest overvaluation — majority bearish
  • Quality Score: 10.0/10 — Excellent — top-tier fundamentals
  • Value Trap Risk: —/100 — Not scored
  • Fair Value Range: $20.17 – $361.42 (1692% spread)

Bullish Models

2 / 13

Bearish Models

11 / 13

Quality Score

10.0 /10

Excellent — top-tier fundamentals

Value Trap Risk

— /100
Not scored

Not scored

Model Consensus

13 /13
Active Models

Avg. confidence: 50%

Investment Thesis

The Bull Case

Target: $361.42 (+259.0% upside)

  • According to the CirclFi Quality of Company (QOC) framework, Abbott Laboratories's quality score of 10.0/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation.
  • According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model targets a fair value of $361.42 (+259.0%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
  • Industry tailwind: therapeutic area leadership could provide meaningful support for Abbott Laboratories's revenue and margin trajectory in the Medical Devices space.
  • The company's $175.3B market capitalization provides liquidity, stability, and the resource base to invest through downturns — structural advantages over smaller peers.

The Bear Case

Target: $20.17 (-80.0%)

  • According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $20.17 (-80.0%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +339.0% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
  • Industry headwind: drug pricing legislation represents a meaningful risk for Abbott Laboratories and its Medical Devices peers.

Peer Benchmarking

DXCM DexCom, Inc.
10.0
IRMD iRadimed Corporation
10.0
PODD Insulet Corporation
10.0
INMD InMode Ltd.
9.9
HAE Haemonetics Corporat
9.8

See full Medical Devices rankings →

Valuation Divergence

Spread

1692%

Fair Value Range

$20.17 – $361.42

A 1692% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

Markov DDM

$361.42 (+259.0%)

Most Bearish

Dynamic NAV

$20.17 (-80.0%)

Key Risk Factors

Model Disagreement

1692% spread signals high variance in projections.

Bearish Consensus

11/13 models suggest overvaluation.

Macro/Sector Risk

Medical Devices headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View ABT Data Page →

The Bottom Line

Our valuation engine sends a clear cautionary signal on Abbott Laboratories at $100.67. 10/13 models flag overvaluation, composite fair value sits at $84.67 (-15.9%), and the risk-reward profile appears unfavorable. Quality at 10.0/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Abbott Laboratories's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy ABT stock right now?

Based on CirclFi's multi-model analysis, 2 of 13 models see upside for ABT at $100.67. The models are divided, which means the investment case depends heavily on your assumptions about Abbott Laboratories's future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Abbott Laboratories?

Key risks include: wide model disagreement (1692% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.

How does ABT compare to its competitors?

Among Medical Devices peers, ABT holds a Quality Score of 10.0/10. Comparable companies include DXCM (QOC 10.0), IRMD (QOC 10.0), PODD (QOC 10.0). The relative ranking helps investors identify whether ABT offers better fundamental quality than alternatives in the same sector.

Is ABT a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ABT's Quality Score of 10.0/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy ABT at?

CirclFi does not provide target buy prices or price alerts. However, our 13 active models produce fair value estimates ranging from $20.17 to $361.42. At $100.67, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for ABT.

View ABT Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →